« Return to News | Clinical Intelligence

The CenterWatch Monthly, December 2012

Monday, December 3, 2012 09:00 AM

Publicity, regulation tightening reins on use of KOLs

Doctors used to consider it an honor to be chosen as “key opinion leaders” (KOLs) by life sciences companies. They were able to help develop new treatments. They garnered the prestige of being considered thought leaders in their areas. And they got paid, sometimes quite handsomely. Drug and device makers, in return, received advice that helped them attune products to what patients really needed. And they basked in the prestige of the most respected medical figures. But bad press and congressional investigations into the cozy relationship between doctors and drug sponsor companies have changed the…

 

Time may be right to makeover the investigator brochure

In drug development, the investigator’s brochure (IB) has long served as the central reference document about an investigational product. It is intended to equip clinical researchers with what they need to make an unbiased risk-benefit assessment of the experimental medicine involving human subjects. But by virtue of its size and complexity, the IB rarely gets a thorough reading, and anecdotal evidence suggests the time and expense invested in its creation reap a relatively modest return. Rethinking the way the IB is developed and utilized may present major opportunities to educate study staff and motivate enrollment, as well as help detect and deter potential…

 

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.